Nicox SA announced consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company’s revenues totaled EUR 0.07 million, compared to EUR 7.5 million for the same period of 2012, which included receipt of a significant milestone payment from Bausch + Lomb. Net loss was EUR 4.3 million compared to a net profit of EUR 4.2 million for the three months to March 31, 2012. This situation is explained by the strong decrease in revenues recognized over the period compared to the first three months of 2012 which included a significant milestone payment from partner Bausch + Lomb. Operating loss was EUR 4.3 million, compared to an operating profit of EUR 4 million on March 31, 2012. Loss before income tax was EUR 4,289,000 compared to profit before income tax of EUR 4,181,000 a year ago.

Nicox S.A. announced that the Company's Board of Directors has nominated Vicente Anido, Jr., PhD., to be elected to the Board. Dr. Anido is a highly respected and experienced leader in the ophthalmology sector. He most recently served as President and Chief Executive Officer of ISTA Pharmaceuticals prior to its acquisition by Bausch + Lomb. The election of Dr. Anido to Nicox's Board will be voted on at the Company's 2013 Ordinary Shareholder Meeting, which will be convened for June 6, 2013. From 2001 to 2012, Dr. Anido was President, Chief Executive Officer and a Director of ISTA Pharmaceuticals.

Nicox SA reported cash flow of €77.5 million on December 31, 2012. The company is looking for acquisition opportunities. The company stated that it is evaluating merger and acquisition opportunities, product acquisitions and licensing agreements for products at an advanced stage of development or already marketed. The company is already negotiating with potential partners.